Lineage Cell Therapeutics Stock Price To Sales

LCTX Stock

USD 0.50 0.10 16.67%

Lineage Cell Therapeutics fundamentals help investors to digest information that contributes to Lineage Cell's financial success or failures. It also enables traders to predict the movement of Lineage Stock. The fundamental analysis module provides a way to measure Lineage Cell's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Lineage Cell stock.

		Last Reported	Projected for Next Year
	Price To Sales Ratio	21.04	19.99

Price To Sales Ratio is likely to drop to 19.99 in 2024.

This module does not cover all equities due to inconsistencies in global equity categorizations. Continue to Equity Screeners to view more equity screening tools.

Lineage Cell Therapeutics Company Price To Sales Analysis

Lineage Cell's Price to Sales ratio is typically used for valuing equity relative to its own past performance as well as to performance of other companies or market indexes. In most cases, the lower the ratio, the better it is for investors. However, it is advisable for investors to exercise caution when looking at price-to-sales ratios across different industries.

P/S

MV Per Share

Revenue Per Share

More About Price To Sales | All Equity Analysis

Current Lineage Cell Price To Sales

18.32 X

Most of Lineage Cell's fundamental indicators, such as Price To Sales, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Lineage Cell Therapeutics is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.

Lineage Price To Sales Driver Correlations

Understanding the fundamental principles of building solid financial models for Lineage Cell is extremely important. It helps to project a fair market value of Lineage Stock properly, considering its historical fundamentals such as Price To Sales. Since Lineage Cell's main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Lineage Cell's historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Lineage Cell's interrelated accounts and indicators.

	Total Assets	Total Stockholder Equity	Net Debt	Retained Earnings	Accounts Payable	Total Liab	Total Current Assets	Common Stock	Current Deferred Revenue	Short Term Debt	Intangible Assets	Net Tangible Assets	Capital Surpluse	Deferred Long Term Liab	Treasury Stock	Property Plant Equipment	Long Term Debt	Net Receivables	Long Term Debt Total	Short Term Investments	Short Long Term Debt	Net Invested Capital	Net Working Capital	Capital Stock	Good Will
Total Assets		0.86	-0.57	-0.71	0.1	0.55	0.75	0.83	0.45	-0.53	0.13	0.79	-0.81	0.24	0.86	0.61	-0.08	0.48	0.12	0.24	0.59	-0.4	0.4	0.4	-0.05
Total Stockholder Equity	0.86		-0.3	-0.45	0.14	0.14	0.52	0.62	0.04	-0.38	-0.14	0.94	-0.66	-0.1	0.77	0.53	-0.26	0.29	0.06	0.24	0.54	-0.25	0.24	0.1	0.17
Net Debt	-0.57	-0.3		0.47	0.1	-0.52	-0.6	-0.48	-0.55	0.32	-0.1	-0.29	0.55	-0.31	-0.48	-0.25	-0.19	-0.4	-0.2	0.37	-0.09	0.24	-0.17	-0.32	0.23
Retained Earnings	-0.71	-0.45	0.47		0.03	-0.72	-0.62	-0.97	-0.68	0.34	-0.51	-0.36	0.81	-0.62	-0.85	-0.69	0.14	-0.27	0.12	-0.39	-0.5	0.86	-0.09	-0.82	0.48
Accounts Payable	0.1	0.14	0.1	0.03		-0.16	0.03	-0.01	-0.29	-0.32	-0.11	0.16	-0.18	-0.34	0.11	-0.03	0.01	0.1	0.21	-0.04	0.21	0.15	0.1	-0.33	0.28
Total Liab	0.55	0.14	-0.52	-0.72	-0.16		0.76	0.65	0.96	-0.18	0.55	0.02	-0.43	0.84	0.48	0.26	-0.14	0.65	-0.25	0.29	0.4	-0.66	0.5	0.82	-0.31
Total Current Assets	0.75	0.52	-0.6	-0.62	0.03	0.76		0.62	0.64	-0.36	0.42	0.32	-0.61	0.37	0.62	0.46	-0.02	0.8	-0.03	0.35	0.41	-0.49	0.71	0.48	0.15
Common Stock	0.83	0.62	-0.48	-0.97	-0.01	0.65	0.62		0.6	-0.4	0.39	0.56	-0.86	0.52	0.92	0.72	-0.19	0.29	-0.09	0.36	0.55	-0.79	0.13	0.74	-0.44
Current Deferred Revenue	0.45	0.04	-0.55	-0.68	-0.29	0.96	0.64	0.6		0.0	0.45	-0.04	-0.37	0.93	0.42	0.23	-0.14	0.55	-0.26	0.15	0.33	-0.67	0.34	0.86	-0.49
Short Term Debt	-0.53	-0.38	0.32	0.34	-0.32	-0.18	-0.36	-0.4	0.0		-0.15	-0.41	0.55	0.18	-0.42	-0.3	-0.27	-0.14	-0.4	-0.11	0.0	0.0	-0.13	0.11	-0.23
Intangible Assets	0.13	-0.14	-0.1	-0.51	-0.11	0.55	0.42	0.39	0.45	-0.15		-0.39	-0.21	0.43	0.17	0.22	-0.05	0.32	-0.39	0.36	0.27	-0.46	0.32	0.6	-0.16
Net Tangible Assets	0.79	0.94	-0.29	-0.36	0.16	0.02	0.32	0.56	-0.04	-0.41	-0.39		-0.64	-0.15	0.74	0.5	-0.18	0.13	0.22	0.07	0.42	-0.15	0.05	-0.01	0.06
Capital Surpluse	-0.81	-0.66	0.55	0.81	-0.18	-0.43	-0.61	-0.86	-0.37	0.55	-0.21	-0.64		-0.21	-0.95	-0.75	-0.07	-0.22	-0.22	-0.27	-0.5	0.55	-0.1	-0.45	0.23
Deferred Long Term Liab	0.24	-0.1	-0.31	-0.62	-0.34	0.84	0.37	0.52	0.93	0.18	0.43	-0.15	-0.21		0.29	0.1	-0.33	0.31	-0.46	0.2	0.26	-0.71	0.11	0.91	-0.65
Treasury Stock	0.86	0.77	-0.48	-0.85	0.11	0.48	0.62	0.92	0.42	-0.42	0.17	0.74	-0.95	0.29		0.77	-0.13	0.27	0.07	0.34	0.62	-0.67	0.13	0.54	-0.26
Property Plant Equipment	0.61	0.53	-0.25	-0.69	-0.03	0.26	0.46	0.72	0.23	-0.3	0.22	0.5	-0.75	0.1	0.77		0.28	0.18	0.35	0.32	0.44	-0.51	0.06	0.39	-0.24
Long Term Debt	-0.08	-0.26	-0.19	0.14	0.01	-0.14	-0.02	-0.19	-0.14	-0.27	-0.05	-0.18	-0.07	-0.33	-0.13	0.28		-0.16	0.88	-0.2	-0.16	0.4	-0.08	-0.33	0.16
Net Receivables	0.48	0.29	-0.4	-0.27	0.1	0.65	0.8	0.29	0.55	-0.14	0.32	0.13	-0.22	0.31	0.27	0.18	-0.16		-0.2	0.05	0.28	-0.25	0.88	0.3	0.15
Long Term Debt Total	0.12	0.06	-0.2	0.12	0.21	-0.25	-0.03	-0.09	-0.26	-0.4	-0.39	0.22	-0.22	-0.46	0.07	0.35	0.88	-0.2		-0.23	-0.05	0.39	-0.17	-0.45	0.23
Short Term Investments	0.24	0.24	0.37	-0.39	-0.04	0.29	0.35	0.36	0.15	-0.11	0.36	0.07	-0.27	0.2	0.34	0.32	-0.2	0.05	-0.23		0.33	-0.46	0.27	0.37	0.19
Short Long Term Debt	0.59	0.54	-0.09	-0.5	0.21	0.4	0.41	0.55	0.33	0.0	0.27	0.42	-0.5	0.26	0.62	0.44	-0.16	0.28	-0.05	0.33		-0.4	0.28	0.45	-0.06
Net Invested Capital	-0.4	-0.25	0.24	0.86	0.15	-0.66	-0.49	-0.79	-0.67	0.0	-0.46	-0.15	0.55	-0.71	-0.67	-0.51	0.4	-0.25	0.39	-0.46	-0.4		-0.03	-0.88	0.51
Net Working Capital	0.4	0.24	-0.17	-0.09	0.1	0.5	0.71	0.13	0.34	-0.13	0.32	0.05	-0.1	0.11	0.13	0.06	-0.08	0.88	-0.17	0.27	0.28	-0.03		0.13	0.37
Capital Stock	0.4	0.1	-0.32	-0.82	-0.33	0.82	0.48	0.74	0.86	0.11	0.6	-0.01	-0.45	0.91	0.54	0.39	-0.33	0.3	-0.45	0.37	0.45	-0.88	0.13		-0.65
Good Will	-0.05	0.17	0.23	0.48	0.28	-0.31	0.15	-0.44	-0.49	-0.23	-0.16	0.06	0.23	-0.65	-0.26	-0.24	0.16	0.15	0.23	0.19	-0.06	0.51	0.37	-0.65

Click cells to compare fundamentals

Lineage Price To Sales Historical Pattern

Today, most investors in Lineage Cell Stock are looking for potential investment opportunities by analyzing not only static indicators but also various Lineage Cell's growth ratios. Consistent increases or drops in fundamental ratios usually indicate a possible pattern that can be successfully translated into profits. However, when comparing two companies, knowing each company's price to sales growth rates may not be enough to decide which company is a better investment. That's why investors frequently use a static breakdown of Lineage Cell price to sales as a starting point in their analysis.

Lineage Cell Price To Sales

Timeline

The most critical factor to remember is that the price of equity takes a firm's debt into account, whereas the sales indicators do not consider financial leverage. Generally speaking, Price to Sales ratio shows how much market values every dollar of the company's sales.

Competition

Predict Lineage Cell

Price To Sales Ratio Over Time

Lineage Price To Sales Ratio

Price To Sales Ratio

19.99

At this time, Lineage Cell's Price To Sales Ratio is fairly stable compared to the past year.

Based on the latest financial disclosure, Lineage Cell Therapeutics has a Price To Sales of 18.3159 times. This is 14.41% lower than that of the Biotechnology sector and 81.39% lower than that of the Health Care industry. The price to sales for all United States stocks is 60.38% lower than that of the firm.

Lineage Price To Sales Peer Comparison

Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Lineage Cell's direct or indirect competition against its Price To Sales to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Lineage Cell could also be used in its relative valuation, which is a method of valuing Lineage Cell by comparing valuation metrics of similar companies.

Lineage Cell is currently under evaluation in price to sales category among its peers.

Lineage Fundamentals

	Return On Equity	-0.35
	Return On Asset	-0.13
	Operating Margin	(4.17) %
	Current Valuation	91.16 M
	Shares Outstanding	188.84 M
	Shares Owned By Insiders	0.44 %
	Shares Owned By Institutions	50.56 %
	Number Of Shares Shorted	15.94 M
	Price To Earning	3.62 X
	Price To Book	1.83 X
	Price To Sales	18.32 X
	Revenue	8.95 M
	Gross Profit	13.97 M
	EBITDA	(24.73 M)
	Net Income	(21.49 M)
	Cash And Equivalents	66.36 M
	Cash Per Share	0.39 X
	Total Debt	2.95 M
	Debt To Equity	0.04 %
	Current Ratio	3.01 X
	Book Value Per Share	0.36 X
	Cash Flow From Operations	(28.57 M)
	Short Ratio	35.21 X
	Earnings Per Share	(0.10) X
	Target Price	4.57
	Number Of Employees	68
	Beta	1.28
	Market Capitalization	113.3 M
	Total Asset	101.02 M
	Retained Earnings	(384.86 M)
	Working Capital	20.48 M
	Current Asset	12.84 M
	Current Liabilities	2.74 M
	Net Asset	101.02 M

About Lineage Cell Fundamental Analysis

The Macroaxis Fundamental Analysis modules help investors analyze Lineage Cell Therapeutics's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Lineage Cell using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Lineage Cell Therapeutics based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.

Please read more on our fundamental analysis page.

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

RSI	Rush Street Interactive
OKTA	Okta Inc
BAC	Bank of America

Additional Tools for Lineage Stock Analysis

When running Lineage Cell's price analysis, check to measure Lineage Cell's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Lineage Cell is operating at the current time. Most of Lineage Cell's value examination focuses on studying past and present price action to predict the probability of Lineage Cell's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Lineage Cell's price. Additionally, you may evaluate how the addition of Lineage Cell to your portfolios can decrease your overall portfolio volatility.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC